# US 2012/0252874 A1 · Methods for delivery of sirna to the spinal cord and therapies arising therefrom

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2012/0252874 A1
- Document ID: US20120252874A1
- Status: Published application
- Kind: A1
- Application number: 13/508,493
- Filed: 2010-11-08
- Published: 2012-10-04
- Earliest claimed: 2009-11-08
- Assignees: Quark Pharmaceuticals, Inc.; Rutgers, The State University of New Jersey
- Inventors: Elena Feinstein; Martin Grumet
- Web page: https://patentgrep.com/patent/US20120252874A1

## CPC

- C12N 15/1138: {against receptors or cell surface proteins}
- A61K 9/0085: {Brain, e.g. brain implants; Spinal cord}
- A61K 31/713: Double-stranded nucleic acids or oligonucleotides
- A61K 45/06: Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A61P 25/00: Drugs for disorders of the nervous system
- A61P 29/00: Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A61P 31/04: Antibacterial agents
- A61P 31/12: Antivirals
- A61P 35/00: Antineoplastic agents
- A61P 39/06: Free radical scavengers or antioxidants
- C12N 15/111: {General methods applicable to biologically active non-coding nucleic acids}
- C12N 15/1135: {against oncogenes or tumor suppressor genes}
- C12N 15/1137: {against enzymes (viral enzymes C12N15/1131; receptors C12N15/1138)}
- C12N 2310/14: interfering nucleic acids [NA]
- C12N 2320/32: Special delivery means, e.g. tissue-specific
- Y10T 436/143333: Saccharide [e.g., DNA, etc.]
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- Y10T: TECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION

## Abstract

The present application relates at least in part to methods for the administration of small interfering RNAs (siRNAs) to the spinal cord of a human or animal patient and also to a method of treatment for spinal cord injury and other diseases and disorders of the CNS. In particular, the application discloses methods to deliver an siRNA compound locally, directly and without the need for transduction vehicles and formulations in effective doses to the injured spinal cord to promote recovery of CNS function and or attenuation of allodynia.

## Claims

### Claim 1

A method of treating or preventing neuropathic pain in a subject, comprising administering to the subject a double stranded RNA compound directed to a target gene selected from RhoA or TLR4, in an amount effective to treat or prevent neuropathic pain in the subject.

### Claim 2 (depends on 1)

The method of claim 1, wherein the double stranded RNA compound is administered by lumbar injection.

### Claim 3

The method of claim or 1, wherein the neuropathic pain is associated with spinal cord injury or with peripheral nervous system injury.

### Claim 4 (depends on 3)

The method of claim 3, wherein the neuropathic pain is associated with spinal cord injury.

### Claim 5 (depends on 4)

The method of claim 4, wherein the spinal cord injury comprises nerve trauma or ischemic injury.

### Claim 6 (depends on 3)

The method of claim 3, wherein the neuropathic pain comprises allodynia.

### Claim 7 (depends on 1)

The method of claim 1, wherein the double-stranded RNA is a chemically modified siRNA.

### Claim 8 (depends on 1)

The method of claim 1, wherein the subject is a human.

### Claim 9 (depends on 3)

The method of claim 3, wherein the double-stranded RNA is administered to the subject up to 48 hours post injury.

### Claim 10 (depends on 9)

The method of claim 9, wherein the double-stranded RNA is administered to the subject up to 24 hours post injury.

### Claim 11 (depends on 1)

The method of claim 1, wherein the neuropathic pain is associated with a condition selected from the group consisting of traumatic nerve injury, post-ischemia, fibromyalgia, reflex sympathetic dystrophy, complex regional pain syndrome, sciatica, phantom limb pain, diabetic neuropathy, and cancer chemotherapeutic-induced neuropathic pain.

### Claim 12 (depends on 1)

The method of claim 1, wherein the neuropathic pain is caused by a malignant tumor, stroke, postherpetic neuralgia, neuropathy with monoclonal protein, vasculitic neuropathy, neuropathy associated with Guillain-Barre syndrome, neuropathy associated with Fabry's disease, an inflammatory condition, an autoimmune disorder including multiple sclerosis, a toxin, a drug, a hereditary abnormality, a mastectomy, or an amputation.

### Claim 13

A method of treating a subject suffering from a disease, a disorder or an injury of the CNS associated with expression of a target gene, comprising locally administering to the subject's spine a double stranded RNA compound directed to the target gene in an amount effective to treat the subject, wherein the target gene is selected from a gene set forth in Table A.

### Claim 14 (depends on 13)

The method of claim 13, wherein the target gene is selected from the group consisting of RhoA and TLR4.

### Claim at position 15

15-25. (canceled)

### Claim 26 (depends on 1)

The method of claim 1, wherein the method further comprises administering to the subject a pharmacological agent selected from a non-steroidal anti-inflammatory drug (NSAID), a steroidal anti-inflammatory drug, anti-inflammatory agent, an antibiotic, an anti-viral agent, a free radical scavenger, an anti-cancer agent and a chemotherapeutic agent or any combination thereof, for simultaneous, concurrent, separate or sequential use in treating the subject.

### Claim 27

A method for restoring motor function in a subject, comprising locally administering to subject's spine a double stranded RNA compound directed to a target gene associated with a loss of motor function in the subject, in an amount effective to restore motor function in the subject.

### Claim at position 18

28-30. (canceled)

### Claim 31

A method of attenuating pain associated with expression of a target gene in a CNS in a subject suffering from injury of the CNS, comprising administering to the subject a double stranded RNA compound directed to the target gene, in an amount effective to attenuate pain in the subject, wherein the double stranded RNA compound is administered by lumbar injection.

### Claim 32

(canceled)

### Claim 33

A method of preserving white matter in the spinal cord of a subject suffering from injury of the CNS, comprising administering to the subject a double stranded RNA compound directed to a target gene in the CNS, in an amount effective to preserve white matter in the subject, wherein the double stranded RNA compound is administered by lumbar injection.

### Claim 34

A method of preventing allodynia or promoting serotonergic fiber growth in a subject suffering from an injury of the CNS, comprising administering to the subject a double stranded RNA compound directed to a target gene in the CNS, in an amount effective to prevent allodynia or promote serotonergic fiber growth in the subject, wherein the double stranded RNA compound is administered by lumbar injection.

### Claim at position 23

35-37. (canceled)

### Claim 38 (depends on 13)

The method of claim 13, wherein the method further comprises administering to the subject a pharmacological agent selected from a non-steroidal anti-inflammatory drug (NSAID), a steroidal anti-inflammatory drug, anti-inflammatory agent, an antibiotic, an anti-viral agent, a free radical scavenger, an anti-cancer agent and a chemotherapeutic agent or any combination thereof, for simultaneous, concurrent, separate or sequential use in treating the subject.
